Corcept Therapeutics shares plunge after FDA rejects hormonal drug

Name: Corcept Therapeutics shares plunge after FDA rejects hormonal drug
Uploaded: 2025-12-31T20:55:38Z
Duration: 23 s
Description: Corcept Therapeutics shares plummeted by over 51% after the FDA declined to approve its drug for a rare hormonal disorder. The FDA's decision was based on its inability to arrive at a favorable benefit-risk assessment without additional evidence, creating a significant regulatory roadblock for the company.

The Claman Countdown · FBN · Dec 31, 2025 · 23sSign Up Now

Already a subscriber?

Corcept Therapeutics shares plummeted by over 51% after the FDA declined to approve its drug for a rare hormonal disorder. The FDA's decision was based on its inability to arrive at a favorable benefit-risk assessment without additional evidence, creating a significant regulatory roadblock for the company.